In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients.
COVID-19
Direct virus neutralization assay S1
Quantitative serology
SARS-CoV-2
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
25
03
2021
accepted:
28
05
2021
pubmed:
18
6
2021
medline:
18
6
2021
entrez:
17
6
2021
Statut:
ppublish
Résumé
Quantitative serological assays detecting response to SARS-CoV-2 are needed to quantify immunity. This study analyzed the performance and correlation of two quantitative anti-S1 assays in oligo-/asymptomatic individuals from a population-based cohort. In total, 362 plasma samples (108 with reverse transcription-polymerase chain reaction [RT-PCR]-positive pharyngeal swabs, 111 negative controls, and 143 with positive serology without confirmation by RT-PCR) were tested with quantitative assays (Euroimmun Anti-SARS-CoV-2 QuantiVac enzyme-linked immunosorbent assay [EI-S1-IgG-quant]) and Roche Elecsys Quantitative anti-S1 serology correlated well with each other (true positives, 96%; true negatives, 97%). Antibody titers decreased over time (< 30 to > 240 days after initial positive RT-PCR). Agreement with GenScript-cPass was 96%/99% for true positives and true negatives, respectively, for Ro-RBD-Ig-quant and 93%/97% for EI-S1-IgG-quant. Ro-RBD-Ig-quant allowed distinct separation between positives and negatives, and less non-specific reactivity versus EI-S1-IgG-quant. Raw values (95% CI) ≥ 28.7 U/mL (22.6-36.4) for Ro-RBD-Ig-quant and ≥ 49.8 U/mL (43.4-57.1) for EI-S1-IgG-quant predicted NT > 1:5 in 95% of cases. Our findings suggest both quantitative anti-S1 assays (EI-S1-IgG-quant and Ro-RBD-Ig-quant) may replace direct neutralization assays in quantitative measurement of immune protection against SARS-CoV-2 in certain circumstances. However, although the mean antibody titers for both assays tended to decrease over time, a higher proportion of Ro-RBD-Ig-quant values remained positive after 240 days.
Sections du résumé
BACKGROUND
BACKGROUND
Quantitative serological assays detecting response to SARS-CoV-2 are needed to quantify immunity. This study analyzed the performance and correlation of two quantitative anti-S1 assays in oligo-/asymptomatic individuals from a population-based cohort.
METHODS
METHODS
In total, 362 plasma samples (108 with reverse transcription-polymerase chain reaction [RT-PCR]-positive pharyngeal swabs, 111 negative controls, and 143 with positive serology without confirmation by RT-PCR) were tested with quantitative assays (Euroimmun Anti-SARS-CoV-2 QuantiVac enzyme-linked immunosorbent assay [EI-S1-IgG-quant]) and Roche Elecsys
RESULTS
RESULTS
Quantitative anti-S1 serology correlated well with each other (true positives, 96%; true negatives, 97%). Antibody titers decreased over time (< 30 to > 240 days after initial positive RT-PCR). Agreement with GenScript-cPass was 96%/99% for true positives and true negatives, respectively, for Ro-RBD-Ig-quant and 93%/97% for EI-S1-IgG-quant. Ro-RBD-Ig-quant allowed distinct separation between positives and negatives, and less non-specific reactivity versus EI-S1-IgG-quant. Raw values (95% CI) ≥ 28.7 U/mL (22.6-36.4) for Ro-RBD-Ig-quant and ≥ 49.8 U/mL (43.4-57.1) for EI-S1-IgG-quant predicted NT > 1:5 in 95% of cases.
CONCLUSIONS
CONCLUSIONS
Our findings suggest both quantitative anti-S1 assays (EI-S1-IgG-quant and Ro-RBD-Ig-quant) may replace direct neutralization assays in quantitative measurement of immune protection against SARS-CoV-2 in certain circumstances. However, although the mean antibody titers for both assays tended to decrease over time, a higher proportion of Ro-RBD-Ig-quant values remained positive after 240 days.
Identifiants
pubmed: 34137000
doi: 10.1007/s40121-021-00475-x
pii: 10.1007/s40121-021-00475-x
pmc: PMC8208377
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1505-1518Investigateurs
Emad Alamoudi
(E)
Jared Anderson
(J)
Valeria Baldassare
(V)
Maximilian Baumann
(M)
Marieke Behlen
(M)
Marc Becker
(M)
Jessica Beyerl
(J)
Rebecca Böhnlein
(R)
Isabel Brand
(I)
Anna Brauer
(A)
Vera Britz
(V)
Jan Bruger
(J)
Friedrich Caroli
(F)
Lorenzo Contento
(L)
Alina Czwienzek
(A)
Flora Deák
(F)
Emma Dech
(E)
Laura Dech
(L)
Maximillian N Diefenbach
(MN)
Jana Diekmannshemke
(J)
Anna Do
(A)
Gerhard Dobler
(G)
Ute Eberle
(U)
Juergen Durner
(J)
Ute Eberle
(U)
Judith Eckstein
(J)
Tabea Eser
(T)
Philine Falk
(P)
Jonathan Frese
(J)
Stefanie Fischer
(S)
Felix Forster
(F)
Turid Frahnow
(T)
Jonathan Frese
(J)
Günter Fröschl
(G)
Christiane Fuchs
(C)
Mercè Garí
(M)
Marius Gasser
(M)
Sonja Gauder
(S)
Otto Geisenberger
(O)
Christof Geldmacher
(C)
Kristina Gillig
(K)
Elias Golschan
(E)
Vitus Grauvogl
(V)
Jessica Michelle Guggenbuehl Noller
(JM)
Celina Halfmann
(C)
Tim Haselwarter
(T)
Jan Hasenauer
(J)
Arlett Heiber
(A)
Matthias Herrmann
(M)
Stefan Hillmann
(S)
Christian Hinske
(C)
Janna Hoefflin
(J)
Tim Hofberger
(T)
Michael Höfinger
(M)
Larissa Hoffmann
(L)
Sacha Horn
(S)
Kristina Huber
(K)
Christian Janke
(C)
Ursula Kappl
(U)
Charlotte Kiani
(C)
Isabel Klugherz
(I)
Norah Kreider
(N)
Inge Kroidl
(I)
Arne Kroidl
(A)
Magdalena Lang
(M)
Clemens Lang
(C)
Silvan Lange
(S)
Ekaterina Lapteva
(E)
Michael Laxy
(M)
Ronan Le Gleut
(R)
Reiner Leidl
(R)
Felix Lindner
(F)
Alexander Maczka
(A)
Alicia Markgraf
(A)
Paula Matcau
(P)
Rebecca Mayrhofer
(R)
Anna-Maria Mekota
(AM)
Hannah Müller
(H)
Dafni Metaxa
(D)
Leonie Pattard
(L)
Ivana Paunovic
(I)
Claire Pleimelding
(C)
Michel Pletschette
(M)
Michael Pritsch
(M)
Stephan Prückner
(S)
Kerstin Puchinger
(K)
Konstantin Pusl
(K)
Peter Pütz
(P)
Katja Radon
(K)
Elba Raimúndez
(E)
Julius Raschka
(J)
Jakob Reich
(J)
Friedrich Riess
(F)
Camila Rothe
(C)
Elmar Saathoff
(E)
Nicole Schäfer
(N)
Yannik Schälte
(Y)
Paul Schandelmaier
(P)
Lara Schneider
(L)
Sophie Schultz
(S)
Mirjam Schunk
(M)
Lars Schwettmann
(L)
Heidi Seibold
(H)
Peter Sothmann
(P)
Paul Stapor
(P)
Jeni Tang
(J)
Fabian Theis
(F)
Verena Thiel
(V)
Sophie Thiesbrummel
(S)
Eva Thumser
(E)
Niklas Thur
(N)
Julian Ullrich
(J)
Julia Waibel
(J)
Claudia Wallrauch
(C)
Simon Winter
(S)
Julia Wolff
(J)
Pia Wullinger
(P)
Tobias Würfel
(T)
Patrick Wustrow
(P)
Houda Yaqine
(H)
Sabine Zange
(S)
Eleftheria Zeggini
(E)
Thomas Zimmermann
(T)
Lea Zuche
(L)
Informations de copyright
© 2021. The Author(s).
Références
Al-Rohaimi AH, Al OF. Novel SARS-CoV-2 outbreak and COVID19 disease; a systemic review on the global pandemic. Genes Dis. 2020;7(4):491–501.
doi: 10.1016/j.gendis.2020.06.004
European Centre for Disease Prevention and Control. COVID-19 country overviews. Week. 2020;51:2020.
Yan Y, Chang L, Wang L. Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): current status, challenges, and countermeasures. Rev Med Virol. 2020;30(3):e2106.
doi: 10.1002/rmv.2106
Carrillo J, Izquierdo-Useros N, Avila-Nieto C, Pradenas E, Clotet B, Blanco J. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochem Biophys Res Commun. 2020;538:187–91.
doi: 10.1016/j.bbrc.2020.10.108
Petherick A. Developing antibody tests for SARS-CoV-2. Lancet. 2020;395(10230):1101–2.
doi: 10.1016/S0140-6736(20)30788-1
Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA. 2020;323(22):2249–51.
doi: 10.1001/jama.2020.8259
Cheng MP, Yansouni CP, Basta NE, et al. Serodiagnostics for severe acute respiratory syndrome-related Coronavirus 2: a narrative review. Ann Intern Med. 2020;173(6):450–60.
doi: 10.7326/M20-2854
Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020;11(1):4704.
doi: 10.1038/s41467-020-18450-4
Piccoli L, Park YJ, Tortorici MA, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024–42 (e21).
doi: 10.1016/j.cell.2020.09.037
Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120–4.
doi: 10.1038/s41586-020-2381-y
Wang S, Peng Y, Wang R, et al. Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. Nat Commun. 2020;11(1):5752.
doi: 10.1038/s41467-020-19568-1
Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–27.
doi: 10.1038/s41586-020-2798-3
Brouwer PJM, Caniels TG, van der Straten K, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369(6504):643–50.
doi: 10.1126/science.abc5902
Rogers TF, Zhao F, Huang D, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956–63.
doi: 10.1126/science.abc7520
To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565–74.
doi: 10.1016/S1473-3099(20)30196-1
Jaaskelainen AJ, Kuivanen S, Kekalainen E, et al. Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. J Clin Virol. 2020;129:104512.
doi: 10.1016/j.jcv.2020.104512
Kohmer N, Westhaus S, Ruhl C, Ciesek S, Rabenau HF. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. J Clin Virol. 2020;129:104480.
doi: 10.1016/j.jcv.2020.104480
Weidner L, Gansdorfer S, Unterweger S, et al. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays. J Clin Virol. 2020;129:104540.
doi: 10.1016/j.jcv.2020.104540
National S-C-SAEG. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. 2020;20(12):1390–400.
doi: 10.1016/S1473-3099(20)30634-4
Radon K, Saathoff E, Pritsch M, et al. Protocol of a population-based prospective COVID-19 cohort study Munich, Germany (KoCo19). BMC Public Health. 2020;20(1):1036.
doi: 10.1186/s12889-020-09164-9
Pritsch M, Radon K, Bakuli A, et al. Prevalence and risk factors of infection in the representative COVID-19 cohort Munich. Int J Environ Res Public Health. 2021;18(7):3572.
doi: 10.3390/ijerph18073572
Olbrich L, Castelletti N, Schälte Y, et al. A serology strategy for epidemiological studies based on the comparison of the performance of seven different test systems: the representative COVID-19 cohort Munich. medRxiv. 2020. https://doi.org/10.1101/2021.01.13.21249735 .
doi: 10.1101/2021.01.13.21249735
EUROIMMUN anti-SARS-CoV-2 ELISA IgG, Package Insert. 2020.
Beavis KG, Matushek SM, Abeleda APF, et al. Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies. J Clin Virol. 2020;129:104468.
doi: 10.1016/j.jcv.2020.104468
Muench P, Jochum S, Wenderoth V, et al. Development and Validation of the elecsys anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2. J Clin Microbiol. 2020;58(10). https://doi.org/10.1128/JCM.01694-20 .
World Health Organization Expert Committee on Biological Standardization. WHO/BS.2020.2403 Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody, 9–10 December 2020. https://www.who.int/publications/m/item/WHO-BS-2020.2403 . Accessed 16 Feb 2021.
Haselmann V, Ozcurumez MK, Klawonn F, et al. Results of the first pilot external quality assessment (EQA) scheme for anti-SARS-CoV2-antibody testing. Clin Chem Lab Med. 2020;58(12):2121–30.
doi: 10.1515/cclm-2020-1183
Yekutieli D, Benjamini Y. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001;29(4):1165–88.
Tian Y, Lian C, Chen Y, et al. Sensitivity and specificity of SARS-CoV-2 S1 subunit in COVID-19 serology assays. Cell Discov. 2020;6:75.
doi: 10.1038/s41421-020-00224-3
Ouyang J, Isnard S, Lin J, et al. Convalescent plasma: the relay baton in the race for coronavirus disease 2019 treatment. Front Immunol. 2020;11:570063.
doi: 10.3389/fimmu.2020.570063